We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

MicroRNA Panel Distinguishes Benign Moles from Melanoma in the Eye

By LabMedica International staff writers
Posted on 27 Nov 2019
Print article
Image: Photograph of an iris melanoma (Photo courtesy of Wikimedia Commons)
Image: Photograph of an iris melanoma (Photo courtesy of Wikimedia Commons)
A blood test based on a panel of six microRNAs (miRNAs) is able to distinguish non-cancerous nevi from malignant melanoma in the eye.

Uveal melanoma is a cancer of the eye involving the iris, ciliary body, or choroid (collectively referred to as the uvea). Tumors arise from the pigment cells (melanocytes) that reside within the uvea and give color to the eye. These melanocytes are distinct from the retinal pigment epithelium cells underlying the retina that do not form melanomas. When eye melanoma spreads to distant parts of the body, the five-year survival rate is about 15%.

Investigators at the University of Queensland (Brisbane, Australia) previously identified a panel of melanoma-related miRNAs that offered superior sensitivity to currently used serologic markers for cutaneous melanoma progression, recurrence, and survival.

MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. Furthermore, miRNAs play essential roles in tumor development, are stable under diverse analytical conditions, and can be readily detected in body fluids.

The investigators sought to assess their panel of miRNAs in serum from patients with choroidal nevi, localized uveal melanoma, and metastatic uveal melanoma. To this end, they drew blood from subjects presenting with a uveal nevus (n = 10), localized uveal melanoma (n = 50), or metastatic uveal melanoma (n = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensitive real-time PCR system.

Results revealed that a panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and miR-363-3p) showed significant differences between participants with uveal nevi compared with patients with localized and metastatic uveal melanoma. In particular, miR-211 was able to accurately distinguish metastatic disease from localized uveal melanoma. When the six-miRNA panel was evaluated as a group it demonstrated the ability to identify uveal melanoma when four or more miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut off point.

"This blood test was able to detect the difference between a benign mole located at the back of the eye and a melanoma in the eye," said first author Dr. Mitchell Stark, a research fellow at the University of Queensland. "The test also has the potential to show if the melanoma has metastasized and spread to other areas of the body. Moles or nevi in the eye are common, but can be difficult to monitor because changes to their shape or coloring can't always be seen as easily as on the skin. Outcomes are poor for people with melanoma in their eye if their cancer spreads to the liver. Given that having nevi in the eye is fairly common, this test may allow us to better screen these patients for early signs of melanoma formation."

The uveal melanoma paper was published in the November 2019 online edition of the journal Translational Vision Science & Technology.

Related Links:
University of Queensland

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.